Patient-Reported Outcomes of Ugandans Living with 1 **Autoimmune Rheumatic Diseases** 2 3 Short title: PROMs in Rheumatology Clinics in Uganda 5 Felix Bongomin<sup>1,2\*</sup>, MB ChB, M.Sc., FECMM, Maria Sekimpi<sup>1</sup>, MB ChB, 6 Barbra Natukunda<sup>1</sup>, MB ChB, Anthony Makhoba<sup>3,4</sup>, MB ChB, M.MED, 7 and Mark Kaddumukasa<sup>1</sup>, MB ChB, M.MED, PhD 8 9 1. Department of Medicine, College of Health Sciences, Makerere University, Kampala, 10 Uganda 11 2. Department of Immunology and Medical Microbiology, Gulu University Medical 12 School, Gulu, Uganda 13 3. Department of Medicine, St. Francis's Hospital- Nsambya, Kampala, Uganda 14 4. Department of Medicine, Mother Kevin Postgraduate Medical School, Uganda 15 Martyrs University, Kampala, Uganda 16 17 18 19 20 \*Correspondence 21 Felix Bongomin, MB ChB, MSc, FECMM 22 Email: drbongomin@gmail.com Tel: + 256 -784-523-395 23

#### Abstract

25

- Purpose: This study aimed to assess the patient-reported outcomes (PROs) in
- 27 rheumatic patients attending two tertiary rheumatology clinics in Uganda.
- Methods: A cross-sectional, clinical audit of patients aged 16 years or older with a
- 29 confirmed diagnosis of rheumatic disease and receiving disease modifying anti-
- 30 rheumatic drugs (DMARDs) was conducted between September and December
- 2020. Health index and overall self-rated health status were assessed using the ED-
- 5D-5L tool. Comparisons for variables was performed using Student's t-test or Mann-
- Whitney U for continuous numerical data while categorical data was compared using
- either  $\chi^2$  tests or Fisher's exact tests as appropriate.

#### Results:

35

- We enrolled 74 eligible patients: 48 (64.9%) had rheumatoid arthritis (RA), 14
- 37 (18.9%) had systemic lupus erythematosus (SLE), and 12 (16.2%) had other
- autoimmune rheumatic disorders. Majority (n=69, 93.2%) were female with a mean
- ±SD age of 45 ± 17 years. Fourteen (18.9%) patients were on concomitant herbal
- 40 medication while using DMARDs and 26 (35.1%) self-reported at least 1 adverse
- 41 drug reactions to the DMARDS. Any level of problem was reported by 54 (72.5%)
- participants for mobility, 47 (63.5%) for self-care, 56 (75.6%) for usual activity, 66
- 43 (89.1%) for pain and discomfort, and 56 (75.6%) for anxiety/depression. Patients
- 44 with SLE had higher median health index compared to those other autoimmune
- 45 rheumatic disorders (p<0.0001). Overall self-rated health status was comparable
- across clinical diagnoses (p=0.2), but better for patients who received care from
- 47 private (Nsambya Hospital) compared to public hospital (Mulago Hospital) (65 vs. 50,
- 48 p=0.009).
- 49 **Conclusion:** There is a substantial negative impact of autoimmune rheumatic
- 50 diseases on quality of life of patients, especially those receiving care from a public
- 51 facility in Uganda.
- 52 **Keywords:** Autoimmune rheumatic diseases, SLE, rheumatoid arthritis, Health
- index, patient-reported outcomes, DMARDs, Uganda

#### **Clinical Significance**

55

60

61

62

63 64

65 66

67

68

69

- 1. Adverse drug reactions to DMARDs was reported by more than one-third of the patients
- 2. SLE patients have better quality of life compared to patients with other autoimmune rheumatic disease.
  - 3. Concomitant use of herbal medication is common and associated with lower health index and lower overall self-rated health status.
  - 4. Autoimmune rheumatic diseases impose a heavy financial burden on affected patients, over 70% of the study patients required financial support for management of their disease and a high proportion of these patients were not on their DMARD therapy the week prior to their scheduled clinic appoints.

#### Introduction

71

72

73

74

75

76

77

78 79

80

81

82

83

84

85 86

87

88

94

95

Autoimmune rheumatic disorders such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are associated with pain, disability and several comorbid conditions thus significantly impacting on quality of life and overall wellbeing of the affected individuals and their families. Consequently, higher morbidity and mortality rates are observed among these individuals compared to the general population <sup>1,2</sup>. Also, there's a significant individual differences in the day-to-day variability of pain, fatigue, and well-being in patients with rheumatic disease. Therefore, quality of life is central in the care of patients with autoimmune rheumatic diseases and is an important target in therapeutic advances in rheumatology while evaluating or managing these patients with disease modifying anti-rheumatic drugs (DMARDs). <sup>4</sup>

Patient-reported outcomes (PROs) are patient's perspectives on their disease activity, functional status, and quality of life <sup>5</sup>. Patient-reported outcome measures (PROMs), are a set of widely available tools directly capture PROs and are increasingly being used in clinical rheumatology practice and in research to help inform patient-centered care and clinical decision-making even among vulnerable rheumatic patients such as those with low health literacy or English proficiency.<sup>6</sup>

There are no locally validated rheumatic disease specific PROMs in Africa and data on PROs of patients with rheumatic diseases in Africa is scanty, even though these diseases, especially RA and SLE are increasingly being reported in Africa.<sup>7–9</sup> This study aimed to describe PROs of patients with autoimmune rheumatic diseases in two tertiary care centers in Uganda.

#### **Patients and Methods**

#### Study design and settings

This descriptive, cross-sectional clinical audit recruited consecutive outpatients attending two rheumatology clinics at Mulago National Referral Hospital (Mulago Hospital), Kampala, Uganda and St. Francis's Hospital-Nsambya, Kampala, Uganda (Nsambya Hospital) between September and December 2020. Mulago Hospital, located in the capital city, Kampala, is the largest public health facility in Uganda

- serving as a national super-specialized hospital with over 1,000-bed capacity.
- Nsambya Hospital is a faith-based, private-not-for-profit hospital also located in
- 103 Kampala, Uganda.

109

121

#### Study population

- Patients aged 16 years or older with a diagnosis of an autoimmune rheumatologic
- disease diagnosed by one of the two experienced rheumatologists (AM and MK) for
- whom at least one of the DMARDs was prescribed in their last previous clinic visit
- 108 constituted the study population.

#### Data collection

- Data were collected using semi-structured questionnaires administered by the
- treating physicians (the authors) during routine clinical care. This audit was
- anonymous, consisted of semi-structured questions, which were available only in
- English. Data was collected on the following parameters: (1) patient socio-
- demographic characteristics: age, gender, marital status, level of education, current
- employment status, monthly income and financial support from family members; (2)
- 116 Clinical diagnosis: duration of illness, self-reported disease severity, disease flares,
- hospitalization and family history of autoimmune disease; (3) Medication: DMARDs
- used, duration of therapy, source of DMARDs, monthly expenditure on DMARDs,
- satisfaction with treatment, concomitant use of herbal medication, adverse drug
- reactions; (4) Number of additional medications used daily; and (5) co-morbidities

#### Patient-reported outcome measure

- The EQ-5D-5L, a standardized instrument for use as a measure of health outcomes
- consisting of 5 dimensions and 5 levels was administered to the participants <sup>10</sup>. The
- tool has been previously used in sub-Saharan Africa and is being validated in
- Ethiopia <sup>11,12</sup>. The 5 dimensions assessed were mobility, self-care, usual activities,
- pain/discomfort, and anxiety/depression. Each dimension has five levels (no
- 127 problems, slight problems, moderate problems, severe problems, extreme
- problems/unable to). Health state profile was generated from these dimensions and
- levels. Overall self-rated health status was assessed using the visual analogue scale

- 130 (VAS) on which the patient rates his/her perceived health from 0 (the worst
- imaginable health) to 100 (the best imaginable health).

#### Data analysis

132

145

149

150

- Baseline characteristics were summarized using medians and ranges or means and
- standard deviations (SD) for continuous variables and frequencies and percentages
- for categorical variables. Comparisons for variables were performed using Student's
- t-test or Mann-Whitney U (for two group comparisons) and the one-way analysis of
- variance or Kruskall-Wallis (for more than two group comparisons) for continuous
- numerical data. Categorical data were compared using either  $\chi^2$  tests or Fisher's
- exact tests as appropriate. Health state index scores generally range from less than
- 0 (where 0 is the value of a health state equivalent to dead; negative values
- representing values as worse than dead) to 1 (the value of full health) were
- calculated from individual health profiles using crosswalk value sets for Zimbabwe
- (Reference). Statistical analyses were performed using STATA 16.0 and GraphPad
- Prism 8.0. A p<0.05 was considered to indicate statistical significance.

#### Ethical considerations

- This was a clinical audit, evaluating standard of care of patients in our clinics. All
- patients provided written informed consent and the study protocol was in compliance
- with the ethical guidelines of the *Declarations of Helsinki*.

#### Results

#### Sociodemographic characteristics

- A total of 74 eligible patients were studied: 41 (55.4%) from Mulago Hospital and 33
- 152 (44.6%) from Nsambya Hospital. Majority were female (n=69, 93.2%) with a mean
- $\pm$ SD age of 45  $\pm$  17 years. Thirty-one (41.9%) patients were single, 29 (39.1%) had
- received tertiary education and 49 (66. 2%) were not formally employed. The median
- 155 (range) monthly income was 300,000 (30,000 1,000, 000) Ugandan shillings
- 156 (UGX). Fifty-five (74.3%) participants received financial support from their children
- 157 (n=18, 24.3%), other family members (n=15, 20.3%), their spouses (n=12, 16.2%),
- their parents (n=7, 9.5%) or from the church (n=3, 4.1%), **Table 1**.

#### **Clinical characteristics**

159

170

171

172173

174

175

176177

178

179180

181 182

183

184 185

186 187

188

189

Forty-eight (64.9%) patients had RA, 14 (18.9%) had SLE, and 12 (16.2%) had other 160 161 rheumatic disorders namely spondyloarthropathy (n=5), systemic sclerosis (n=3), 162 juvenile idiopathic arthritis (n=2), and inflammatory myopathy (n=2). The median 163 (range) duration of illness was 48 (2-420) months. On the day of the clinic visit, 164 patients' self-rated severity of their illnesses was as follows: Controlled (n=10, 13.5%), mild (n=18, 24.3%), moderate (n=29, 39.2%), severe (n=12, 16.2%), and 165 very severe (n=5, 6.8%). The median (range) episodes of disease flares in the past 3 166 months was 1 (range: 0- 20). Thirty-two (43.2%) patients had at least one co-167 morbidity. Of these, 23 (71.9%) were RA patients, 4 (12.5%) were SLE and 5 168 169 (15.6%) were patients who had other clinical diagnoses.

#### Disease modifying anti-rheumatic drug therapy

None of the patients was on biologic DMARDs. Majority of the patients with RA were on monotherapy of methotrexate (n=23, 47.9%), those with SLE were mostly either on monotherapy of hydroxychloroquine or in a combination with azathioprine (n= 12, 85.7%), and half of patients with other rheumatic diseases were either on azathioprine or sulfasalazine (n=6, 50%), **Table 1**. The median duration of DMARD therapy was 12 (range: 1-24) months. All 41 patients from Mulago Hospital bought their DMARDs from private pharmacies. On the other hand, 16/33 patients from Nsambya Hospital bought their DMARDS from the hospital pharmacy, 13/33 from private pharmacies and 4 from either private pharmacies or Nsambya Hospital pharmacy. The median (range) monthly cost of DMARDs was 120,000 (12,800 -2,000,000) UGX. Sixty-four (86.4%) participants reported satisfaction with DMARD treatment. However, 14 (18.9%) participants were on concomitant herbal medication while using DMARDs. Twenty-six (35.1%) participants reported at least 1 adverse drug reactions (ADRs) to the DMARDs. Most ADRs were observed with methotrexate (10/26; 4 patients reported dizziness, 3 weakness, 2 gastrointestinal (GI) disturbances and 1 pulmonary fibrosis), hydroxychloroquine (8/26: 1 visual impairment, 2 rashes, and 5 dizziness), sulfasalazine (4/26: 1 nightmare, 3 GI disturbance), azathioprine (3/26; all 3 reported weakness), and 1 patient reported diarrhea while on mycophenolate mofetil.

- 190 Twenty-one (28.4%) patients, most of whom were attending Mulago Hospital
- 191 Rheumatology Clinic (18/21 (86%) vs. 3/21 (14%), p=0.01) were off DMARDs in the
- 192 week prior to clinic visit.

194

195

196

197

198 199

200

201

202

203204

205

206

207

208

209

210211

212

213

214

215

216

#### Health profiles and overall health status

Table 3 and Table 4 summarizes the health indices and overall self-rated health status of the participants across sociodemographic and clinical characteristics. Regarding the health profiles of the participants, 71 (96%) participants reported at least one activity limitation. Any level of problem was reported by 54 (72.5%) participants for mobility, 47 (63.5%) for self-care, 56 (75.6%) for usual activity, 66 (89.1%) for pain and discomfort, and 56 (75.6%) for anxiety/depression. The median health index was 0.675 (range: 0.163 – 0.9). Both health index and overall self-rated health status were higher for patients who received care from Nsambya Hospital compared to Mulago Hospital (0.718 vs. 0.585, p<0.0001) and (63.6 vs. 53.7, p<0.0001), respectively **Table 3 and 4**. Also, patients with SLE had higher median health index compared to those with RA or other rheumatic disease, Table 3. Patients who reported controlled or mild disease, and those who reported satisfaction with medical (DMARDs) therapy had higher health indices and higher overall self-rated health status (all p-values <0.001), **Table 3 and 4**. Conversely, patients who reported concomitant herbal medication use had lower health index (0.558 vs. 0.664, p=0.03) and lower overall self-rated health status (47.6 vs. 60.5, p=0.01) compared to those who did not report use of herbal medications, Table 3 and 4. There was a trend towards patients with co-morbidities having a better overall self-reported health status compared to those without co-morbidities (58.6 vs. 57.7, p=0.05), **Table 4**.

#### **Discussion**

217

218

219

220

221222

223

224

225

226

227

228229

230

231

232

233

234

235

236237

238

239

240

241

242

243244

245

246

247

248

Understanding PROs influence treatment decisions and inform clinical care in patients with autoimmune rheumatic disease. 13,14 In the present study, among Ugandan patients with autoimmune rheumatic diseases, over 95% of the patients reported at least one activity limitation. This finding is consistent with the 2020 American College of Rheumatology (ACR) patients survey, where about 83% of people living with a rheumatic disease reported at least one activity limitation as a result of their disease, including ability to exercise, work, and perform physical activities. 15 Our findings suggest that patients with SLE have a better quality of life compared to patients with other autoimmune rheumatic diseases which is in line with prior investigation. 16 Contrastingly, a recent study from Kenya showed that patients with SLE had significantly low health-related quality of life. 17 This is probably because the Kenyan patients had more severe disease, though much younger age than our population. Remarkably, participants with duration of illness of 4 years or less and those who were on DMARDs for less than 1 year had higher health indices. Equally remarkably, overall self-rated health status was comparable across groups and sub groups of illness duration and duration of uninterrupted DMARDs therapy. Age, disease severity and co-morbidities are important predictors of quality of life of patients with autoimmune diseases. 17-19 Thus it was not surprising that in our study, patients with controlled or mild disease and those who reported satisfaction with DMARDS had higher health indices and high self-rated health status. Current rheumatic management guidance emphasizes the treat-to-target approach, as patients in remission or low disease activity tends to have a better quality of life indices 14. However, access and affordability of both conventional and biologic DMARDs remains a challenge worldwide. 15,20 indeed, none of our study participants was on a biologic DMARDS. Lack of access to and non-affordability of DMARDs have negative association with disease activity and a poorer quality of life.<sup>20</sup> This is evident in our study where patients attending care in a private hospital with better access to DMARDs had better health indices and overall self-rated health status. DMARDs are expensive and are unaffordable by most patients. In the 2020 ACR patient survey, the median annual out-of-pocket spending on treatment for rheumatic disease was \$1,000 per year. 15 On average, out-of-pocket expenditure on DMARDs

of our patients was about \$400 per year. This is quite high and explains the high proportion of patients not being on their DMARDs the week prior to their scheduled clinic appoints. In Uganda, much as DMARDs such as methotrexate are on the essential medicine list, they are not routinely available for the care of patients with rheumatic diseases. The heavy financial burden of these diseases and their management explains the huge need for financial support observed in over 70% of our patients. Consequently, patients who are wealthier or have health insurance services are able to access these medicines in private settings and have better adherence and health outcomes as observed in one of the centres in the present study.

One in every 5 patients with rheumatic disease in our cohort reported concomitant use of herbal medication. Regrettably, this was associated with lower health index and lower overall self-rated health status. Despite the fact that ADRs were similar among those who were on herbal medications and those not using herbs, these findings should encourage clinicians to always assess for herbal medication use among these patients and provide appropriate counseling. However, it is unclear whether the poor quality of life of patients on concomitant herbal medication was truly due to negative impacts of herbal medicines on rheumatic diseases or because patients who showed poor response while on DMARDs had uncontrolled disease and therefore sought for herbal remedy for a better disease control. Herbal medication use remains an area of further research among these patients. Known beneficial add-on therapy in patients with rheumatic diseases revolves around optimization of the management of underlying co-morbidities, physical and occupational therapies.<sup>15</sup>

Our study has some important limitations. Firstly, we were unable to assess disease specific severity for the different rheumatic diseases. However, we were able to elicit patients-reported disease severity which fairly correlates with disease severity scores. Secondly, we were unable to formally assess for medication adherence using validated tools due to lack of access to license. Thirdly, we were unable to use disease specific health-related outcome measures such as LupusQoL. However, ED-5D-5L has been shown to be a reliable tool for these group of patients. Lastly, measurements of test–retest reliability were not done because patients were

assessed on only one clinic visit. However, this the first study from Uganda and one of the few in the region to report on quality of life of patients with autoimmune rheumatic diseases receiving DMARDs. Future studies would aim at correlating health indices with disease severity and medication adherence in our setting. At policy level, we need to identify strategies to widely increase availability; accessibility and affordability of DMARDs in Uganda should be explored. It's timely to welcome clinical trials on biologic DMARDs for our patients to evaluate short- and long-term outcomes.

#### **CONCLUSION**

281

282

283

284

285

286

287

288

289

295

301

305

- In conclusion, over 95% of Ugandan patients with autoimmune rheumatic diseases
- on DMARDs have at least one activity limitation. SLE patients have better quality of
- life compared to patients with RA or rheumatic disease. Concomitant use of herbal
- 293 medication is common and associated with lower health index and lower overall self-
- 294 rated health status.

#### Acknowledgement

- Mark Kaddumukasa is supported by a grant from the National Institutes Health
- 297 (K43TW010401 NINDS and Fogarty International Center (FIC). We are indebted to
- 298 our patients who have become a significant part of us and through whom we are
- able to enjoy the practice of clinical rheumatology. We appreciate the administrative
- 300 support from the study sites.

#### **Authors' contribution**

- All authors significantly contributed to the conceptualization, design, data collection,
- analysis and interpretation and drafting of the manuscript. The final manuscript was
- read and approved by all authors.

#### Competing interests

306 All authors have no conflict of interest to declare

#### 307 **Funding**

#### 308 None

#### References

- Zochling J, Braun J. Mortality in rheumatoid arthritis and ankylosing spondylitis. *Clin Exp Rheumatol.* 2009;27(4 SUPPL. 55):S127-30.
- 314 http://www.ncbi.nlm.nih.gov/pubmed/19822059
- 315 2. Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality,
- and comorbidity of the rheumatic diseases. *Arthritis Res Ther.* 2009;11(3):229.
- 317 doi:10.1186/ar2669
- 318 3. Schneider S, Junghaenel DU, Keefe FJ, Schwartz JE, Stone AA, Broderick JE.
- Individual differences in the day-to-day variability of pain, fatigue, and well-being in
- 320 patients with rheumatic disease: Associations with psychological variables. *Pain*.
- 321 2012;153(4):813-822. doi:10.1016/j.pain.2012.01.001
- 322 4. Burmester GR, Bijlsma JWJ, Cutolo M, McInnes IB. Managing rheumatic and
- musculoskeletal diseases past, present and future. *Nat Rev Rheumatol.*
- 324 2017;13(7):443-448. doi:10.1038/nrrheum.2017.95
- 325 5. US Food & Drug Administration. Patient-reported outcome measures: use in medical
- 326 product development to support labeling claims. Published 2009. Accessed
- 327 December 13, 2020. https://www.fda.gov/regulatory-information/search-fda-guidance-
- 328 documents/patient-reported-outcome-measures-use-medical-product-development-
- 329 support-labeling-claims
- 330 6. Carvajal Bedoya G, Davis LA, Hirsh JM. Patient-Reported Outcomes in
- Rheumatology Patients With Limited English Proficiency and Limited Health Literacy.
- 332 Arthritis Care Res (Hoboken). 2020;72(S10):738-749. doi:10.1002/acr.24243
- 7. Phuti A, Schneider M, Makan K, Tikly M, Hodkinson B. Living with systemic lupus
- erythematosus in South Africa: A bitter pill to swallow. Health Qual Life Outcomes.
- 335 2019;17(1). doi:10.1186/s12955-019-1132-y
- 336 8. Usenbo A, Kramer V, Young T, Musekiwa A. Prevalence of Arthritis in Africa: A
- 337 Systematic Review and Meta-Analysis. Nurmohamed M, ed. *PLoS One*.
- 338 2015;10(8):e0133858. doi:10.1371/journal.pone.0133858
- 339 9. Bongomin F, Sekimpi M, Kaddumukasa M. Clinical and immunological characteristics
- of 56 patients with systemic lupus erythematosus in Uganda. Rheumatol Adv Pract.
- 341 2020;4(1). doi:10.1093/rap/rkaa011
- 342 10. EuroQol a new facility for the measurement of health-related quality of life. Health
- 343 Policy (New York). 1990;16(3):199-208. doi:10.1016/0168-8510(90)90421-9
- 344 11. Sibhat SG, Fenta TG, Sander B, Gebretekle GB. Health-related quality of life and its
- predictors among patients with breast cancer at Tikur Anbessa Specialized Hospital,
- Addis Ababa, Ethiopia. Health Qual Life Outcomes. 2019;17(1):165.
- 347 doi:10.1186/s12955-019-1239-1
- 348 12. Welie AG, Gebretekle GB, Stolk E, et al. Valuing Health State: An EQ-5D-5L Value
- Set for Ethiopians. *Value Heal Reg Issues*. 2020;22:7-14.
- 350 doi:10.1016/j.vhri.2019.08.475
- 351 13. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 Update of the EULAR
- recommendations for the management of systemic lupus erythematosus. *Ann Rheum*
- 353 Dis. 2019;78(6):736-745. doi:10.1136/annrheumdis-2019-215089
- 354 14. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against
- Rheumatism/American College of Rheumatology classification criteria for systemic
- 356 lupus erythematosus. *Ann Rheum Dis.* 2019;78(9):1151-1159.

357 doi:10.1136/annrheumdis-2018-214819 358 15. ACR. 2020 Rheumatic Disease Patient Survey Results. Access, Affordability & 359 Lifestyle Challenges for Americans Living with Rheumatic Disease. simpletasks.org/wp-content/uploads/2020/09/ACR-Survey-2020.pdf 360 361 16. Greenfield J, Hudson M, Vinet E, et al. A comparison of health-related quality of life (HRQoL) across four systemic autoimmune rheumatic diseases (SARDs). Abu-362 Shakra M, ed. PLoS One. 2017;12(12):e0189840. doi:10.1371/journal.pone.0189840 363 364 17. Nyambane E, Genga E, Achieng L, Oyoo O, Otieno FC. Assessment of disease 365 activity and health related quality of life in patients with systemic lupus erythematosus at Kenyatta national hospital. African J Rheumatol. 2020;(9.1):A121.2-A122. 366 doi:10.1136/lupus-2020-eurolupus.230 367 Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 Update of the EULAR 368 18. recommendations for the management of systemic lupus erythematosus. Ann Rheum 369 370 Dis. 2019;78(6):736-745. doi:10.1136/annrheumdis-2019-215089 Wadee S, Tikly M, Hopley M. Causes and predictors of death in South Africans with 371 19. 372 systemic lupus erythematosus. Rheumatology. 2007;46(9):1487-1491. 373 doi:10.1093/rheumatology/kem180 374 20. Bergstra SA, Branco JC, Vega-Morales D, et al. Inequity in access to bDMARD care 375 and how it influences disease outcomes across countries worldwide: results from the 376 METEOR-registry. Ann Rheum Dis. 2018;77(10):1413-1420. doi:10.1136/annrheumdis-2018-213289 377 378 21. Zhang L, Luan W, Geng S, et al. Lack of patient education is risk factor of disease 379 flare in patients with systemic lupus erythematosus in China. BMC Health Serv Res. 2019;19(1):378. doi:10.1186/s12913-019-4206-v 380 381 382 383 384 385 386

## **Tables**

387

388

## Table 1: Sociodemographic and clinical characteristics of the participants

Variable	Freq (%)
Centre, n=74	
Mulago Hospital	41 (55.4)
Nsambya Hospital	33 (44.6)
Age, mean ±SD years	45±17
≤45	39 (52.7)
>45	35 (47.3)
Sex, n=74	
Female	69 (93.2)
Male	5 (6.8)
Marital status, n=74	
Single	31 (41.9)
Married	22 (29.7)
Widow/er	13 (17.6)
Divorced	8 (10.8)
Education level, n=74	,
Informal	6 (8.1)
Primary	21 (28.4)
Secondary	18 (24.3)
Tertiary	29 (39.2)
Employment, n=74	
Formal	25 (33.8)
Informal	49 (66.2)
Financial support, n=74	
Yes	55 (74.3)
No	19 (25.7)
Clinical diagnosis, n=74	
RA	48 (64.9)
SLE	14 (18.9)
Others	12 (16.2)
Duration of illness, median, range (months)	48 (2-420)
≤48	40 (54.1)
> 48	34 (45.9)
Self-reported disease severity, n=74	
Controlled	10 (13.5)
Mild	18 (24.3)
Moderate	29 (39.2)
Severe	12 (16.2)
Very severe	5 (6.8)
Satisfaction with medical treatment	
Yes	65 (87.8)
No	9 (12.2)
Use of Herbal medication	
Yes	14 (18.9)
No	60 (81.1)
Adverse drug reactions	
Yes	26 (35.1)
No	48 ( 64.9)
Charlson co-morbidity index, median, range	2 (1-11)
Hypertension	22 (29.7)
/1	\ - /

HIV	3 (4.1)
Chronic Heart Failure	3 (4.1)
Diabetes	3 (4.1)
Treatment regimen by diagnosis, n=74	
Rheumatoid arthritis, n=48	
Methotrexate alone	23 (47.9)
Hydroxychloroquine alone	8 (16.7)
Hydroxychloroquine + Methotrexate	8 (16.7)
Methotrexate + Lefluonomide	6 (12.5)
Hydroxychloroquine + azathioprine	2 (4.2)
Hydroxychloroquine + Methotrexate + Lefluonomide	1 (2.1)
SLE, n=14	
Hydroxychloroquine + azathioprine	8 (57.1)
Hydroxychloroquine alone	4 (28.6)
Hydroxychloroquine + Mycophenolate mofetil	2 (14.3)
Others autoimmune rheumatic diseases, n=12	
Azathioprine alone	3 (25.0)
Sulfasalazine alone	3 (25.0)
Hydroxychloroquine alone	1 (8.3)
Hydroxychloroquine + azathioprine	1 (8.3)
Hydroxychloroquine + Methotrexate	1 (8.3)
Hydroxychloroquine + Sulfasalazine	1 (8.3)
Methotrexate alone	1 (8.3)
Methotrexate + Sulfasalazine	1(8.3)
Source of DMARDS, n=74	
Private pharmacy	54 (73.0)
Nsambya Hospital	16 (26.6)
Nsambya Hospital + private pharmacy	4 (5.4%)
Duration of uninterrupted DMARD therapy,	12 (1-240)
median, Range (months)	.= /
≤12	45 (60.8)
>12	29 (39.2)
Off DMARDs in the last one week	0.1 (0.0.1)
Yes	21 (28.4)
No	53 (71.6)

## Table 2: EQ-5D-5L frequencies and proportions reported by dimension and level

	MOBILITY N (%)	SELF-CARE N (%)	USUAL ACTIVITIES N (%)	PAIN/DISCOMFORT N (%)	ANXIETY/DEPRESSION N (%)
LEVEL 1 NO PROBLEMS	20 (27.0)	27 (36.5)	18 (24.3)	8 (10.8)	18 (24.3)
LEVEL 2 SLIGHT PROBLEMS	26 (35.1)	23 (31.1)	26 (35.1)	23 (31.1)	26 (35.1)
LEVEL 3 MODERATE PROBLEMS	15 (20.3)	15 (20.3)	20 (27.0)	26 (35.1)	20 (27.0)
LEVEL 4 SEVERE PROBLEMS	12 (16.2)	8 (10.8)	6 (8.1)	17 (23)	8 (10.8)
LEVEL 5 EXTREME PROBLEMS/UNABLE TO DO	1 (1.4)	1 (1.4)	4 (5.4)	0 (0)	2 (2.7 )
TOTAL	74 (100)	74 (100)	74 (100)	74 (100)	74 (100)

391

392

393

## Table 3: Health indices of the participants across sociodemographic and clinical characteristics

Variable	Freq (%)	Health index Mean (SD)	p-value
ALL, n=74	74 (100%)	0.644 ± 0.164	-
Centre, n=74			
Mulago Hospital	41 (55.4)	0.585 ±0.177	< 0.0001
Nsambya Hospital	33 (44.6)	0.718 ±0.110	
Age, year			
≤45	39 (52.7)	$0.657 \pm 0.138$	0.516
>45	35 (47.3)	$0.632 \pm 0.185$	
Sex, n=74	()		
Female	69 (93.2)	$0.637 \pm 0.162$	0.160
Male	5 (6.8)	$0.744 \pm 0.177$	
Marital status, n=74	04 (44 0)	0.070 0.400	0.000
Single	31 (41.9)	$0.673 \pm 0.169$	0.633
Married	22 (29.7)	$0.629 \pm 0.144$	
Widow/er Divorced	13 (17.6)	$0.611 \pm 0.212$ $0.628 \pm 0.105$	
Education level, n=74	8 (10.8)	$0.020 \pm 0.105$	
Informal	6 (8.1)	0.675 ± 0.139	0.227
Primary	21 (28.4)	$0.675 \pm 0.139$ $0.594 \pm 0.162$	0.221
Secondary	18 (24.3)	$0.625 \pm 0.169$	
Tertiary	29 (39.2)	$0.686 \pm 0.162$	
Employment, n=74	20 (00.2)	0.000 ± 0.102	
Formal	25 (33.8)	0.672 ± 0.172	0.302
Informal	49 (66.2)	$0.630 \pm 0.159$	0.002
Financial support, n=74	10 (0012)	0.000 = 0.1100	
Yes	55 (74.3)	0.637 ± 0.161	0.528
No	19 (25.7)	0.665 ± 0.665	
Clinical diagnosis, n=74			
RA	48 (64.9)	0.601 ± 0.173	0.007
SLE	14 (18.9)	$0.738 \pm 0.121$	
Others	12 (16.2)	$0.704 \pm 0.097$	
Duration of illness, median, range (months),	48 (2-420)	$0.644 \pm 0.164$	
, n=74			
≤48	40 (54.1)	$0.682 \pm 0.125$	0.029
> 48	34 (45.9)	$0.599 \pm 0.193$	
Self-reported disease severity, n=74	10 (10 5)	0.740 0.440	0.0004
Controlled	10 (13.5)	$0.740 \pm 0.112$	<0.0001
Mild	18 (24.3)	$0.719 \pm 0.120$	
Moderate	29 (39.2)	$0.650 \pm 0.158$	
Severe	12 (16.2)	$0.467 \pm 0.090$	
Very severe Satisfaction with medical treatment	5 (6.8)	$0.572 \pm 0.234$	
Yes	65 (87.8)	0.668 ± 0.145	0.001
No	9 (12.2)	$0.472 \pm 0.194$	0.001
Use of Herbal medication	5 (12.2)	U.712 EU.134	
Yes	14 (18.9)	0.558 ± 0.231	0.03
No	60 (81.1)	$0.664 \pm 0.139$	3.00
Adverse drug reactions	(0.11)	1.00 . 2 01.00	
Yes	26 (35.1)	0.627 ± 0.181	0.516
No	48 ( 64.9)	$0.653 \pm 0.155$	
	( )		

395

Co-morbidity			
Yes	32 (43.2)	$0.642 \pm 0.170$	0.91
No	42 (56.8)	$0.646 \pm 0.161$	
Source of DMARDS, n=74			
Private pharmacy	54 (73.0)	$0.644 \pm 0.164$	0.196
Nsambya Hospital	16 (26.6)	$0.709 \pm 0.099$	
Nsambya Hospital + private pharmacy	4 (5.4%)	$0.649 \pm 0.102$	
Duration of uninterrupted DMARD	12 (1-240)	$0.646 \pm 0.161$	
therapy, median, Range (months), n=74			
≤12	45 (60.8)	$0.675 \pm 0.133$	0.042
>12	29 (39.2)	$0.594 \pm 0.195$	
Off DMARDs in the last one week			
Yes	21 (28.4)	$0.622 \pm 0.185$	0.771
No	53 (71.6)	$0.652 \pm 0.180$	

# Table 4: Overall self-rated health status of the participants across sociodemographic and clinical characteristics

Variable	Freq (%)	Overall self-rated health status	p-value
		Mean (SD)	
ALL, n=74	74 (100%)	58.1 ± 16.7	-
Centre, n=74			
Mulago Hospital	41 (55.4)	53.7± 17.2	0.01
Nsambya Hospital	33 (44.6)	63.6 ± 14.3	
Age, year	, ,		
≤45	35 (47.3)	58.6 ± 15.6	0.823
>45	39 (52.7)	57.7 ± 17.8	
Sex, n=74	( /		
Female	69 (93.2)	57.6 ± 16.6	0.342
Male	5 (6.8)	65.0 ± 18.0	
Marital status, n=74	- ( )		
Single	31 (41.9)	57.1 ± 18.9	0.874
Married	22 (29.7)	59.8 ± 15.7	
Widow/er	13 (17.6)	59.6 ± 15.9	
Divorced	8 (10.8)	55.0 ± 12.8	
Education level, n=74	2 (15.5)		
Informal	6 (8.1)	60.8 ± 20.1	0.849
Primary	21 (28.4)	55.5 ± 14.0	0.010
Secondary	18 (24.3)	59.4 ± 16.2	
Tertiary	29 (39.2)	58.6 ± 18.6	
Employment, n=74	20 (00.2)	00.0 ± 10.0	
Formal	25 (33.8)	61.0 ± 16.6	0.290
Informal	49 (66.2)	56.6 ± 16.7	0.230
Financial support, n=74	40 (00.2)	00.0 ± 10.7	
Yes	55 (74.3)	58.2 ± 16.9	0.949
No	19 (25.7)	57.9 ± 16.4	0.545
Duration of illness, median, range	48 (2-420)	58.1 ± 16.7	
(months), n=74	40 (Z 4Z0)	00.1 ± 10.7	
≤48	40 (54.1)	61.3 ± 15.4	0.079
> 48	34 (45.9)	54.4 ± 17.5	
Clinical diagnosis, n=74	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\		
RA	48 (64.9)	55.7 ± 17.4	0.225
SLE	14 (18.9)	63.9 ± 17.0	
Others	12 (16.2)	60.8 ± 11.4	
Self-reported disease severity, n=74	( - /		
Controlled	10 (13.5)	72.5 ± 14.4	<0.0001
Mild	18 (24.3)	65.0 ± 13.1	
Moderate	29 (39.2)	55.5 ± 15.2	
Severe	12 (16.2)	45.0 ± 15.5	
Very severe	5 (6.8)	51.0 ± 15.6	
Satisfaction with medical treatment			
Yes	65 (87.8)	60.8 ± 15.0	<0.0001
No	9 (12.2)	38.9 ± 16.4	.5.5551
Use of Herbal medication	• ( )		
Yes	14 (18.9)	47.9 ± 23.2	0.01
No	60 (81.1)	$60.5 \pm 14.0$	3.01
Adverse drug reactions	(01.1)	20.0 = 1.1.0	
7 ta vo 100 alay loadiidiid			

\/	00 (05 4)	<b>55.0</b> 40.4	0.000
Yes	26 (35.1)	57.9 ± 13.4	0.933
No	48 ( 64.9)	58.2 ± 18.3	
Co-morbidity			
Yes	32 (43.2)	58.6 ± 17.7	0.05
No	42 (56.8)	57.7 ± 16.1	
Source of DMARDS, n=74			
Private pharmacy	54 (73.0)	55.7 ± 17.0	0.829
Nsambya Hospital	16 (26.6)	66.3 ± 14.9	
Nsambya Hospital + private pharmacy	4 (5.4%)	58.8 ± 10.3	
Duration of uninterrupted DMARD therapy, median, Range (months), n=74	12 (1-240)	57.9 ± 17.0	
≤12	45 (60.8)	57.8 ± 15.4	0.922
>12	29 (39.2)	$58.2 \pm 20.0$	
Off DMARDs in the last one week			
Yes	21 (28.4)	58.1 ± 21.5	0.817
No	53 (71.6)	59.4 ± 11.0	
			·